Using the clinically-validated 176.5mg dose shows a commitment to evidence-based formulation rather than just marketing hype
It usually improves as your body adapts, but it can feel unpleasant in the meantime
Clinical trials often reveal a pattern of quick initial weight loss that eventually levels off
Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
AMPK: a metabolic gauge regulating whole-body energy homeostasis